Skip to content

Multicenter Prospective Clinical Study of Neoadjuvant Therapy Combined with Low-carbohydrat Diet for Non-Small Cell Lung Cancer

Prospective Clinical Study of Neoadjuvant Therapy Combined with Low-carbohydrat Diet for Non-Small Cell Lung Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086294
Enrollment
Unknown
Registered
2024-06-28
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

Neoadjuvant Therapy + Low-Carbohydrate Diet Group:Neoadjuvant Therapy + Low-Carbohydrate Diet
Neoadjuvant Therapy Group:Neoadjuvant Therapy

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate and sign the informed consent form; 2.Age = 18 years; 3. Pathologically and histologically confirmed stage II-III NSCLC; 4. Suitable for receiving radical resection and neoadjuvant therapy before surgery; 5. Willing to adhere to a low-carbohydrate diet.

Exclusion criteria

Exclusion criteria: 1. Suffering from chronic pancreatitis or alcoholism (drinking more than 3 standard cups per day; or at least one instance of drinking =5 standard cups per week); 2. Having diseases related to fatty acid transport and oxidation disorders, such as carnitine deficiency or porphyria; 3. History of symptomatic gallstones (except those who have undergone cholecystectomy); 4. Pregnant or breastfeeding women; 5.Patients with eating disorders, severe mental illness, or those unable to adhere to a low-carbohydrate diet for other reasons; 6.Currently participating in or having participated in other clinical studies within 4 weeks prior to the start of this study; 7.Investigators deem the subject has diseases that affect outcome evaluation or is unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Event-Free Survival Rate;

Secondary

MeasureTime frame
Mortality Rate;Incidence of Adverse Events;Major Pathological Response Rate;

Countries

China

Contacts

Public ContactJun Yin

Shanghai Sixth People's Hospital

yinjun@sjtu.edu.cn+86 21 2405 8337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026